The answer: constipation occurs more often in treatment groups
In pooled STEP 1–3 data, constipation was reported by 24.2% receiving semaglutide 2.4 mg and 11.1% receiving placebo. This describes the studied product and population; it is not a guaranteed rate for every GLP-1 preparation.[1]
The placebo rate is an important reminder that constipation also occurs without the treatment. A new symptom during treatment still deserves attention, but its cause should not be decided solely from the date on which a prescription began. Existing bowel patterns, other medicines and changes in eating are relevant context.
Constipation is more than going less often
NIDDK describes constipation through several features: infrequent bowel movements, hard or lumpy stools, difficulty or pain passing stool, and a feeling of incomplete evacuation. People’s usual patterns differ.[2]
| Detail | A useful description |
|---|---|
| Frequency | How the current pattern differs from your usual pattern |
| Consistency | Hard, dry or lumpy stools versus a usual stool |
| Difficulty | Straining, pain or incomplete evacuation |
| Associated symptoms | Abdominal pain, vomiting, bleeding or inability to pass gas |
A person who goes less often after eating much less may describe a different problem from someone with painful hard stools or increasing abdominal discomfort. The table is a way to communicate the distinction, not a scoring system or a diagnostic rule. No single number of days can safely classify every situation.
What an assessment may need
NIDDK describes reviewing medical history, medicines and supplements, diet, activity and bowel symptoms. Testing depends on the clinical situation rather than being automatic for everyone. Tracking the pattern can help a clinician assess the change.[3]
- BaselineWhat was normal before the change?
- ContextWhat changed in medicines, food, fluid or routine?
- AssessmentWhat response fits the symptoms and medical history?
Include nonprescription products in the medication list. Otherwise, the clinician may see the new GLP-1 medicine but miss another change made at the same time. Similarly, a food log does not need to become a restrictive calorie exercise; a short account of what changed may be enough to explain the context.
Why a universal laxative plan is a poor substitute
General constipation guidance includes food, fluid and activity changes, with medicines selected according to the situation. NIDDK advises discussing medication changes with a healthcare professional rather than stopping or changing them independently.[4]
A generic online schedule can overlook another cause of symptoms, a restriction on fluid intake, other medicines, or signs that require examination. Combining several remedies also makes it harder to know what helped and what caused a new problem. Treatment should follow an assessment of the actual pattern rather than a provider’s standard shipping calendar.
Seek prompt medical assessment for severe or persistent abdominal pain, vomiting, bleeding, or inability to pass gas. These symptoms should not be handled as a routine subscription question. An online clinical inbox can support ongoing care but is not an emergency service.
Choose a service with a usable follow-up route
Our Lavender Sky Health review separates consultation and refill arrangements, and QuickMD’s review examines visit-based access. The provider tool can help compare those practical differences. Read the nausea evidence article for why adverse-event percentages do not describe symptom duration or determine the right response for an individual.
For a different treatment concern, read the semaglutide hair-loss evidence explainer.